DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Market sizing and forecasting
Increased accuracy and confidence to better evaluate market opportunities and allocation of investments

How we help
Our approach
Blended data sources
What our clients say
Resources

Research teams need to obtain faster and more timely answers to their business questions. Because of evolving market dynamics, it is increasingly essential that pharmas get their forecasting right, whether for a broad therapy area or a sub-population of patients. However, most research methods have limitations that can result in inaccurate forecasts -- with costly repercussions.

Decision Resources Group’s data scientists and epidemiologists combine epidemiology with real-world data, helping pharma teams gain a deep understanding of a disease population for more accurate forecasting and greater confidence in planning commercial investments.

How we help
DRG combines epidemiology and real-world data so research teams can:
Benchmark your forecasts with data on the total potential and addressable market

Validate your investments using bottom-up forecasting

Identify growth opportunities and understand how populations will change over time

Track disease stages, sub-populations and treatment flow

Estimate drug-treated populations with insights from therapeutic experts and primary market research

Our approach
We partner with brand teams to answer tough business questions, laying the groundwork for precise forecasting and strategic implementation:

Segment by therapy area

Segment by sub-population

Key questions:

  • How big is the market opportunity? Does this market warrant pursuit?
  • What is the overall prevalence and the drug-treated prevalence for this condition?​
  • What comorbid conditions do relevant patients have?​
  • How many untreated patients have this condition?​
  • What does the physician profile look like for these patients?
  • What are key differences between patients receiving my drug versus competitor drugs?​
  • What specialties most commonly diagnose these patients or initiate treatment?​
  • What are common referral patterns and who are the various HCPs that patients interact with throughout their healthcare journey?
  • Where are patients treated? What sites of care matter most?

Blended data sources

By fusing multiple data sources, true market opportunity is revealed, sales force teams are optimized, and commercial effectiveness is enabled:

Accurate sizing and forecasting enabled by diverse data sources and therapeutic and data experts


Claims

  • 26 billion claims
  • Visibility into 300+ million patients total
  • 220+ million patients captured annually
  • 2+ million healthcare providers
  • 98% of 750 U.S. payers, real-time updates
  • Hospitals, physician offices, ASCs, pharmacies, long-term care, nursing facilities


Health plan formulary & lives

  • 4,500+ formularies & restrictions data from 781 US payers (>90%)
  • 100% of US population enrollment data by coverage type
  • Hospital formulary data from 240 IDNs

Electronic health records

  • Visibility into 100+ million patients (over 3 years)
  • Diagnoses, diagnostic tests, assessments, vaccines, vitals, Rx

Social data

  • Anonymized social conversation data from public social platforms, online communities and message boards

Epidemiology

  • Coverage of 220+ diseases, vaccines and tumor biomarkers across up to 171 countries

Healthcare provider affiliation directory

  • 6.5+ million affiliations
  • Affiliations among 3,200 hospital systems and 2+ million HCPs

What our clients say

"Working with the DRG team showed me the power of linking claims with EHR for sizing and understanding patient populations and the impact on your business decisions – that was a lightbulb moment for me. I really value that partnership of being able to call up my DRG specialist to brainstorm how to use this integrated data to tackle our most challenging questions."

Epidemiology lead at pharma company

Resources
Briefings
Picturing the hidden patient: Overcoming challenges in sizing and segmentation for rare diseases and niche treatments

Briefings
Integrated Patient Journey; one journey, many lenses

Case Study
How can we size our potential market when the population is difficult to define?

Want to learn more?
Contact us to connect with a DRG specialist on how we can support your market sizing needs